NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
Clinical Trials
23 trialsNCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT03086538 2022-06-15
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT01397305 2020-09-09
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01953419 2016-07-28
Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy
Sun Yat-sen University
Phase 2 Completed
NCT00701857 2016-04-20
Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
University of Arizona
Phase 1 Completed
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT01909830 2015-06-19
Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT00166465 2011-03-14
Stage IV Colorectal CA ALIMTA
Mayo Clinic
Phase 1/2 Completed
NCT00191984 2011-01-05
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00415168 2010-08-17
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00320515 2009-09-28
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00330915 2009-07-21
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00191412 2007-11-20
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
Eli Lilly and Company
Phase 2 Completed
NCT00490373 2007-06-22
Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic
Eli Lilly and Company
Phase 2 Completed
NCT00190801 2007-01-26
Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00034619 2006-07-19
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00035035 2006-07-19
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Eli Lilly and Company
Phase 3 Completed